Shares in Proteome were trading up 12% at
The study was published in 'Alzheimers & Dementia:
Using data from three international studies, it took blood samples from a total of 1,148 individuals and analysed them for 26 proteins that had previously shown a connection to Alzheimer's.
From this study, the company identified 10 proteins capable of predicting whether patients with mild cognitive impairment would develop Alzheimer's within a year, which it said has an accuracy of 87%.
Proteome said that it was selecting commercial partners to combine these protein biomarkers in a blood test for the global market.
The company said the study was a "major advance" in developing a blood test for the disease, and such a test would be easier and less expensive than using brain imaging or cerebrospinal fluid.
Most Popular Stories
- Toxic Algae Threatens Florida Fishing, Tourism
- Stocks Rise Before Fed Statement
- Fed Signals It Will Keep Key Rate at Record Low
- Occupy Wall Street Buys Up Student Debt
- Eva Mendes Gives Birth to a Baby Girl
- Hispanic Groups Lead Voter Registration Drive
- Cool Features on Today's New iOS 8
- Kohl's Hiring 67,000 for the Holidays
- FedEx Adding 50,000 Holiday Jobs
- Plus-Size iPhones Live Up to The Hype